Identifying active compounds of soursop ethanolic fraction as α-glucosidase inhibitor

Authors

  • Eko Mugiyanto Sekolah Tinggi Ilmu Kesehatan Muhammadiyah Pekajangan Pekalongan http://orcid.org/0000-0001-9777-4800
  • Agung Nur Cahyanta Department of Pharmacy, STIKES Bhamada Slawi
  • I Made Agus Sunadi Putra Department of Pharmacology, Universitas Mahasaraswati
  • Siswa Setyahadi Department of Biotechnology, Indonesian Agency for the Assessment and Application of Technology
  • Partomuan Simanjuntak Department of Biotechnology, Indonesian Institute of Sciences

DOI:

https://doi.org/10.12928/pharmaciana.v9i2.10105

Keywords:

Muricatin, cis-Reticulin, Methylquercetin, Saccharomyces cerevisiae

Abstract

Postprandial hyperglycemia is triggered by two enteric proteins (α-amylase and α-glucosidase) connected to the brush border of intestinal cells. In diabetic populations, Type 2 Diabetes Mellitus is more prevalent, and α-glucosidase inhibition is the suitable therapy for delaying glucose intake after meals. This study was designed to investigate chemical compounds for their potential inhibitory effects on α-glucosidase. It employed a spectrophotometric method with p-nitrophenyl-α-D-glucopyranose from Saccharomyces cerevisiae as an alpha-glucosidase substrate. The ethanolic fraction was acquired from assay- or activity-guided fractionation. The findings showed that the ethanolic fraction of soursop leaves exhibited the most significant inhibitory activity with an IC50 of 0.17 μg/ml. The data analysis and active compounds identification were carried out by LC-MS and FT-IR.  The active compounds of the resulted mixture comprised of Muricatin C, cis-Reticulatacin-10-one, and 3-Methylquercetin 7-[galactosyl-(1->4)-glucoside].

References

Anonymous., 2008, Traditional Medicine. WHO. Available at: http://www.who.int/mediacentre/factsheets/fs134/en/.

Anonymous., 2016, FooDB. Available at: http://foodb.ca/ (Accessed: August 21, 2018).

Bailey, C. and Day, C., 1989, Traditional treatments for diabetes, Diabet Care, 12: 553–554.

Borges de Melo, E., da Silveira Gomes, A.,Carvalho, I., 2006, α- and β-glucosidase inhibitors: chemical structure and biological activity, Tetrahedroadn, 62(44): 10277–10302.

Ceriello, A. 2005. Postprandial hyperglycemia and diabetes complications: is it time to treat?, Diabetes, 54(1):1–7.

Chehade, JM, Mooradian, AD., 2000, A rational approach to drug therapy of type 2 diabetes mellitus, Drugs, 60(1): 95–113.

Koshland, D.E., J., 2008. Stereochemistry and the mechanism of enzymatic reactions, Biological Reviews, 28: 416–436.

Mugiyanto E, Simanjuntak P, Setyahadi S., 2017, Identifikasi Senyawa Aktif Fraksi Etanol Daun Sirsak (Annona muricata Linn.) Sebagai Inhibitor α-AMYLASE, Jurnal Para Pemikir, 6 (2): 131-138.

Ivan A., R., 2003, Medicinal Plant of The World. New York: Springer Science+Business Media.

Moller, D. 2001. New drug targets for type 2 diabetes and the metabolic syndrome, Nature, 414: 821–827.

Murray 2003, Biokimia Harper’s. 25th ed. Jakarta: EGC Japan.

Oberlies, N, Chang CJ, McLaughlin JL., 1997, Structure–activity relationships of diverse Annonaceous acetogenins against multidrug resistant human mammary adenocarcinoma (MCF – 7/Adr) cells, Journal of Medicinal Chemistry. 40(13): 2102–2106.

Oki, T., Matsui, T. and Osajima, Y. 1999. Inhibitory effect of alpha-glucosidase inhibitors varies according to its origin, Journal of Agricultural and Food Chemistry, 47(2): 550–553.

Padma P, Pramod NP, Thyagarajan SP, and Khosa RL., 1998, Effect of the extract of Annona muricata and Petunia nyctaginiflora on Herpes simplex virus. J Ethnopharmacol. 61(1):81-83.

Quezada-Calvillo, R, C.C. Robayo-Torres, A.R. Opekun, Sen, P, et al., 2007, Contribution of mucosal maltase-glucoamylase activities to mouse small intestinal starch α-glucogenesis, Journal of Nutrition, 137(7): 1725–1733.

Shaw J., 2010, Global estimates of the prevalence of diabetes for 2010 and 2030. - PubMed - NCBI. Available at: https://www.ncbi.nlm.nih.gov/pubmed/19896746 (Accessed: February 11, 2018).

Srinivasan, K., Kaul, C. L., and Ramarao, P., 2005, Partial protective effect of rutin on multiple low dose streptozotocin-induced diabetes in mice. Indian Journal of Pharmacology, 37 (5): 327–328.

Soumya, P. R., K. A. Choudary, D. M. Kar, Lopamudra DAS, Avijeet, J., 2009, Traditional Medicinal System – Future Source of New Drugs., International Journal of Pharmacy And Pharmaceutical Science, 1(1): 1–23.

Tadera, K., Minami, Y., Takamatsu, K., and Matsuoka, T., 2006, Inhibition of R-Glucosidase and R- Amylase by Flavonoids. J. Nutr. Sci. Vitaminol. 52: 149–153.

Zimmet, P., K.G, Alberti, J. Shaw., 2001, Global and societal implications of the diabetes epidemic, Nature. Edited by K. G. Alberti, 414(6865): 782–787.

Downloads

Published

2019-11-30

Issue

Vol. 9 No. 2 (2019): Pharmaciana

Section

Analytical Pharmacy and Medicinal Chemistry

License

Authors who publish with Pharmaciana agree to the following terms:

  1. Authors retain copyright and grant the journal the right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC BY-SA 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal. 
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.